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failure (HF) remains controversial. A puriﬁed cardiac glycoside derived from the foxglove plant, digoxin increases
ejection fraction, augments cardiac output, and reduces pulmonary capillary wedge pressure without causing
deleterious increases in heart rate or decreases in blood pressure. Moreover, it is also a neurohormonal modulator
at low doses. In the pivotal DIG (Digitalis Investigation Group) trial, digoxin therapy was shown to reduce all-cause
and HF-speciﬁc hospitalizations but had no effect on survival. With the discovery of neurohormonal blockers capable
of reducing mortality in HF with reduced ejection fraction, the results of the DIG trial were viewed as neutral, and the
use of digoxin declined precipitously. Although modern drug and device-based therapies have dramatically improved
the survival of ambulatory patients with HF, outcomes for patients with worsening chronic HF, deﬁned as
deteriorating signs and symptoms on standard therapy often leading to unscheduled clinic or emergency
department visits or hospitalization, have largely remained unchanged over the past 2 decades. The available data
suggest that a therapeutic trial of digoxin may be appropriate in patients with worsening chronic heart failure who
remain symptomatic. (J Am Coll Cardiol 2014;63:1823–32) ª 2014 by the American College of Cardiology
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It was decided to proceed with the proposal for digitalization.
There was no dyspnea on lying ﬂat.
The lungs were entirely clear.
dDr. Howard G. Bruenn on treating
President Franklin D. Roosevelt (2)
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Table 1
Prevalence of Digo
in Representative
Patients Admitted
Registry
ADHERE
OPTIMIZE-HF
EFHS II
EFICA
RO-AHFS
IN-HF Outcome
ATTEND
Reported as overall percentages or divided
ADHERE ¼ Acute Decompensated Hear
pensated Heart Failure Syndromes; EF ¼
EFICA ¼ Etude Française de l’Insufﬁsance
Registry on Heart Failure; OPTIMIZE-HF ¼
Hospitalized Patients With Heart Failure; RO
Abbreviations
and Acronyms
CI = conﬁdence interval
CV = cardiovascular
EF = ejection fraction
HF = heart failure
HR = heart rate
NYHA = New York Heart
Association
RR = risk ratio
SDC = serum digoxin
concentration
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1824Although the management of
ambulatory patients withHFwith
reduced EF has been revolution-
ized over the past couple of de-
cades by drug and device-based
therapies with a mortality beneﬁt
(17), patients with worsening
chronic HF, deﬁned as deterio-
rating signs and symptoms on
standard therapy often leading to
unscheduled clinic or emergency
department visits or hospitaliza-
tions, remain at high risk for
admission or death (18,19). Toconfront this growing challenge, the Centers for Medicare
and Medicaid Services have implemented ﬁnancial disin-
centive for hospitals with excessive 30-day readmissions for
HF. Given this ﬁnancial impetus, it is an opportune time to
reconsider existing therapies capable of reducing HF-related
hospitalizations and readmissions (18,20). Thus, in this re-
view we seek to critically reevaluate the available data on the
role of digoxin in the contemporary management of HF and
to provide a conceptual framework for future research.
Mechanism of Action
Digoxin and other cardiac glycosides function by inhibiting
the membrane-bound Naþ/Kþ–adenosine triphosphatase,
thereby impeding the transport of sodium from the intra-
cellular to the extracellular space (21). The resulting loss of
the transmembrane sodium gradient decreases the activity
of the Naþ/Ca2þ exchanger, disrupting Ca2þ homeostasis
and increasing intracellular levels. In myocytes, raising
the intracellular Ca2þ concentration, the pivotal link in
excitation-contraction coupling, increases inotropy and the
force generated (22–24). As a result, in patients with systolic
dysfunction, digoxin improves left ventricular EF, augments
cardiac output, and reduces pulmonary capillary wedge
pressure without causing deleterious increases in heart rate
(HR) or decreases in blood pressure (Table 2) (25–28).xin Use at Admission and Discharge
Hospital-Based Registries of
With Primary Diagnoses of HF
Admission Discharge
30/19 44/21
30/17 38/19
27 31
19 17
35 40
16 w24
w15 w25
into reduced/preserved EF.
t Failure National Registry; ATTEND ¼ Acute Decom-
ejection fraction; EFHS ¼ EuroHeart Failure Survey;
Cardiaque Aiguë; HF ¼ heart failure; IN-HF ¼ Italian
Organized Program to Initiate Lifesaving Treatment in
-AHFS ¼ Romanian Acute Heart Failure Syndromes.For many years, it was thought that digoxin exerted its
effects primarily in the myocardium, but it is now recognized
that the physiologic properties of digoxin are a result of
inhibition of Naþ/Kþ–adenosine triphosphatase in cardiac
and noncardiac tissues alike (29). In noncardiac tissue,
digoxin acts as a neurohormonal modulator by increasing
parasympathetic tone and decreasing activation of the sym-
pathetic nervous system and renin-angiotensin-aldosterone
system (27,30–32). Furthermore, in addition to its direct
sympatholytic effects at low doses, digoxin indirectly de-
creases sympathetic outﬂow by improving carotid sinus
baroreceptor sensitivity. Although digoxin improves the
overall neurohormonal proﬁle in patients with severe HF at
low doses, it should be noted that further dose increases
within the therapeutic range have no added neurohormonal
beneﬁt and may in fact be sympathomimetic (33,34).
Finally, digoxin slows ﬁring at the sinoatrial node and
prolongs conduction at the atrioventricular node but has
limited electrophysiological effects on the remainder of the
conduction system. Thus, digoxin has minimal proarrhyth-
mic effects when dosed to achieve guideline-recommended
serum digoxin concentrations (SDCs) (14–16). In contrast,
at supratherapeutic SDCs or therapeutic SDCs with
concomitant hypokalemia, atrioventricular block and escape
rhythms are the most common electrocardiographic mani-
festations of toxicity.Digoxin Withdrawal Trials
Before the pivotal DIG trial, numerous small to medium-
sized randomized, double-blind, placebo-controlled trials
provided evidence that digoxin improves hemodynamics
and clinical status in ambulatory patients with HF with
reduced EF receiving background therapy including diuretic
agents with or without oral vasodilators (35). The most
compelling evidence was derived from PROVED (Pro-
spective Randomized Study of Ventricular Function and
Efﬁcacy of Digoxin) (36) and RADIANCE (Randomized
Assessment of Digoxin on Inhibitors of the Angiotensin
Converting Enzyme) (37) trials, which tested the hypothesis
that digoxin withdrawal from background therapy would
lead to clinical deterioration. Both studies enrolled stable
ambulatory patients with HF with EFs 35% and New
York Heart Association (NYHA) functional class II or III
symptoms in normal sinus rhythm and randomized themTable 2 Physiologic Effects of Digoxin Therapy
Hemodynamic Neurohormonal Electrophysiological
[ LVEF [ Parasympathetic SA node: slows sinus rate
[ CO Y Sympathetic AV node: prolongs conduction
Y HR,4 BP Y RAAS
Y PCWP
Modiﬁed and reprinted, with permission, from Gheorghiade et al. (4).
AV ¼ atrioventricular; BP ¼ blood pressure; CO ¼ cardiac output; HR ¼ heart rate; LVEF ¼ left
ventricular ejection fraction; PCWP ¼ pulmonary capillary wedge pressure; RAAS ¼ renin-
angiotensin-aldosterone system; SA ¼ sinoatrial.
Figure 1
Pooled Retrospective Analysis of the PROVED
and RADIANCE Trials Showing the Incidence
of Worsening HF by Treatment Strategy
*p < 0.01 compared to all other groups. ACEI ¼ angiotensin-converting inhibitor;
Dig ¼ digitalis; Diur ¼ diuretic agent; HF ¼ heart failure; PROVED ¼ Prospective
Randomized Study of Ventricular Function and Efﬁcacy of Digoxin; RADIANCE ¼
Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting
Enzyme. Reprinted, with permission, from Young et al. (39).
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1825to either continue digoxin therapy or switch to placebo
in addition to background therapy for 12 weeks. In the
PROVED and RADIANCE protocols, the investigators
were encouraged to optimize background HF therapy,
which, respectively, included diuretic agents and diuretic
agents plus angiotensin-converting enzyme inhibitors.
In both trials, digoxin continuation led to a lower inci-
dence of treatment failure (deﬁned as subjective and objec-
tive evidence of worsening HF severe enough to require a
therapeutic intervention), improved exercise tolerance, and
increased left ventricular EF (Table 3). Among patients
receiving diuretic agents and angiotensin-converting enzyme
inhibitors, continuation of digoxin also led to fewer signs
and symptoms of volume overload and better quality-of-life
scores. However, the relative clinical efﬁcacy of digoxin may
be overstated in these studies because digoxin was removed
from a previously stable medication regimen. In contrast, a
substudy of the DIG trial examining health-related quality
of life found that digoxin improved only perceived health at
4 months but had no discernible effect on any of the do-
mains assessed at 12 months (38). Finally, pooled retro-
spective analyses of the PROVED and RADIANCE trials
suggested that triple therapy with digoxin in addition to
an angiotensin-converting enzyme inhibitor and a diuretic
agent was associated with the lowest incidence of worsening
HF and found that digoxin therapy reduced overall health
care expenditures, setting the stage for the pivotal DIG trial
(Fig. 1) (39,40).
The DIG Trial
The DIG main trial was self-described as a “simple” phase
III trial cosponsored by the National Heart, Lung, andTable 3
Effects of Digoxin in Stable Ambulatory Patients
With HF in Normal Sinus Rhythm With Reduced EF
Receiving Diuretic Agents (PROVED) or Diuretic
Agents and ACE Inhibitors (RADIANCE)
End Point
On Diuretic
Agents
On ACE Inhibitors
and Diuretic Agents
Treadmill time Improved Improved
6-min walk distance No change Improved
Incidence of treatment failure Decreased Decreased
Time to treatment failure Decreased Decreased
Change in signs and symptoms
of heart failure
No change Improved
Quality of life (Minnesota
Living With Heart Failure
Questionnaire)
No change Improved
CHF score No change Improved
Global evaluation of progress No change Improved
LVEF Improved Improved
HR and BP Decreased Decreased
Body weight Decreased Decreased
Modiﬁed and reprinted, with permission, from Eichhorn et al. (35).
ACE ¼ angiotensin-converting enzyme; CHF ¼ congestive heart failure; EF ¼ ejection fraction;
PROVED ¼ Prospective Randomized Study of Ventricular Function and Efﬁcacy of Digoxin;
RADIANCE ¼ Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting
Enzyme; other abbreviations as in Table 2.Blood Institute and the U.S. Department of Veterans Af-
fairs Cooperative Studies Program, designed to study the
effects of digoxin on mortality and hospitalization in 6,800
stable ambulatory patients with HF with EFs 45% in
normal sinus rhythm, irrespective of digoxin treatment status
at enrollment (6,41). Patients were randomized in a double-
blind fashion to receive digoxin or placebo once daily in
addition to background therapy. The recommended initial
daily dose was determined using an algorithm incorporating
age, sex, weight, and renal function, but ﬁnal dosing was
left to the discretion of the site investigator. Patients treated
with digoxin before enrollment were randomized without a
preceding washout period. Follow-up visits were scheduled
for weeks 4 and 16 and every 4 months thereafter, for a
mean duration of 37 months (range: 28 to 58 months).
Study participants had a mean age of 65 years, were
predominantly white men, and reported NYHA functional
class II or III symptoms (Table 4). Nearly one-half of the
patients were receiving digoxin at the time of enrollment,
and there was high background use of angiotensin-
converting enzyme inhibitors (about 95%) and diuretic
agents (about 80%). More than 80% of digoxin-treated
patients received daily doses of study drug 0.250 mg.
Although all-cause mortality did not differ between the
digoxin and placebo arms (Fig. 2A), there was a trend to-
ward a lower risk for HF-speciﬁc mortality (394 vs. 449
deaths; risk ratio [RR]: 0.88; 95% conﬁdence interval [CI]:
0.77 to 1.01; p ¼ 0.06). In contrast, the incidence of all-
cause, cardiovascular (CV)–related, and HF-related hospi-
talization was signiﬁcantly lower in patients randomized to
digoxin (Table 4). In addition, the incidence of death or
hospitalization for worsening HF (Fig. 2B), although not a
Table 4
Baseline Clinical Characteristics and Outcomes
by Treatment Assignment in the DIG Trial
Clinical Characteristic/
Outcome Digoxin Placebo p Value
Age, yrs 63.4  11.0 63.5  10.8
Women 22.2% 22.5%
Nonwhite race 14.4% 14.8%
NYHA functional class
I 13.7% 13%
II 55.3% 54.5%
III 30.7% 30.5%
IV 2.2% 1.9%
Prior digoxin 44.1% 44.6%
Concomitant therapies
Diuretic agents 81.2% 82.2%
ACE inhibitors 94.1% 94.8%
Nitrates 42.1% 43.1%
Daily dose of study drug, mg
0.125 17.5% 17.4%
0.250 70.6% 70%
0.375 10.3% 11.3%
0.500 1.1% 0.9%
Cause of death
All 34.8% 35.1% 0.80
CV 29.9% 29.5% 0.78
Worsening HF 11.6% 13.2% 0.06
Other CV 15.0% 13.0% d
Reason for hospitalization
All 64.3% 67.1% 0.006
CV 49.9% 54.4% <0.001
Worsening HF 26.8% 34.7% <0.001
Other CV 23.1% 19.7% d
Non-CV/unspeciﬁed 40.7% 39.6% d
Values are mean  SD or %.
ACEI ¼ angiotensin-converting enzyme; CV ¼ cardiovascular; DIG ¼ Digitalis Investigation Group;
HF ¼ heart failure; NYHA ¼ New York Heart Association.
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1826pre-speciﬁed outcome, was signiﬁcantly lower in the digoxin
group (1,041 vs. 1,291 patients; RR: 0.75; 95% CI: 0.69 to
0.82; p < 0.001). Finally, the incidence of hospitalization for
suspected digoxin toxicity was 2-fold higher in digoxin-
treated patients but still relatively low overall (67 vs. 31
events; RR: 2.17; 95% CI: 1.42 to 3.32; p < 0.001).
The DIG ancillary trial had a similar design and was
conducted in parallel to the main study but included patients
with EFs >45% (42). The ancillary trial enrolled a total of
988 patients and found no effects on all-cause, CV-speciﬁc,
or HF-speciﬁc mortality or on all-cause or CV hospitaliza-
tions. However, there was a trend toward a reduction in
hospitalization for worsening HF (108 vs. 89 events; RR:
0.79: 95% CI: 0.59 to 1.04; p ¼ 0.094), which was offset by
a trend toward an increase in hospitalization for unstable
angina (62 vs. 82 events; RR: 1.37; 95% CI: 0.99 to 1.91;
p ¼ 0.061).
Although straightforward in its design, there are a number
of details concerning the DIG trial meriting further
mention. First, the study population was about 5 to 10 years
younger than an unselected population of ambulatory pa-
tients with HF (43) and included few women (about 20%)and racial minorities (<15%), limiting its generalizability.
Second, digoxin was stopped in about 50% of the pati-
ents randomized to placebo, without a washout period, and
>20% of patients in the placebo group received open-label
digoxin at some point during follow-up, which, respec-
tively, would tend to bias the data to reject and accept the
null hypothesis. In addition, digoxin levels were considered
therapeutic if the SDC was between 0.5 and 2.0 ng/ml,
while current guidelines (14,15,44) recommend an SDC
between 0.5 and 0.9 ng/ml. As a result, it is notable that the
mean SDC was 0.86 ng/ml at the 1-month visit and 0.80
ng/ml at the 12-month visit, suggesting that nearly one-half
of the patients enrolled in the DIG trial had supra-
therapeutic SDCs by modern standards, yet digoxin therapy
did not adversely affect survival.
Finally, although digoxin has been part of background
therapy for most pivotal clinical trials, many modern medical
(i.e., b-blockers and mineralocorticoid receptor antagonists)
and device (i.e., implantable cardioverter-deﬁbrillators and/
or cardiac resynchronization therapy) therapies were not
yet a part of background therapy when the DIG trial was
conducted, potentially limiting the applicability of these
data to contemporary clinical practice. Thus, the afore-
mentioned considerations and the differential beneﬁt of
digoxin on HF-speciﬁc morbidity and mortality have made
the DIG trial database an active area of investigation since
its initial publication.
Retrospective Analyses of Digoxin Trials
The revised recommendation suggesting a therapeutic SDC
of 0.5 to 0.9 ng/ml instead of 0.5 to 2.0 ng/ml (14,15,44) is
based on several post-hoc analyses of the DIG trial and
other clinical trial databases suggesting that it may be
possible to obtain the favorable effects of digoxin with an
SDC <1.0 ng/ml (33,34,45–47). Before the DIG trial, it
had been shown that the hemodynamic and neurohormonal
effects of digoxin occur at low digoxin doses and that
increasing the dose does not always results in additional
beneﬁt (33,34,46). Similarly, pooled analysis of the
PROVED and RADIANCE studies found that the effects
of digoxin were comparable at lower (<1.0 ng/ml) and
higher SDCs.
After completion of the DIG trial, a comprehensive post-
hoc analysis including all patients enrolled in the main and
ancillary trials with properly measured SDCs (about 80% of
study participants) was performed to assess the interaction
between SDC and long-term morbidity and mortality (45).
This study found that HF hospitalizations were reduced
in the digoxin arm compared with placebo irrespective of
SDC, while survival was improved only in those patients
randomized to digoxin with SDCs 0.9 ng/ml (Fig. 3). Of
note, the survival beneﬁt was robust and consistent across
age, sex, EF, and comorbid disease states.
There has also been substantial interest in the sex-speciﬁc
effects of digoxin, because women made up only about 20%
Figure 2 All-Cause Mortality and Incidence of Death or Hospitalization for Worsening HF in the DIG Trial
(A) All-cause mortality; (B) incidence of death or hospitalization due to worsening HF. Reprinted, with permission, from the Digitalis Investigation Group (6). DIG ¼ Digitalis
Investigation Group; HF ¼ heart failure.
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1827of total enrollment in the DIG trial. Although initially it had
been suggested that all-cause mortality may have been
increased in women randomized to digoxin (48), subsequent
analysis of the DIG main trial taking into account SDC
found only women with SDCs >1.0 ng/ml to be at higher
risk for mortality (49). Furthermore, compared with placebo,
there was a signiﬁcant inverse relationship between the risk
for all-cause mortality and SDC in both men and women
(Fig. 4). Although in women, the point estimates for the
risk for mortality for SDC <1.0 ng/ml did not reach the
threshold for statistical signiﬁcance, many fewer women
were enrolled in the DIG trial, decreasing statistical power
to detect a difference.
In addition, several retrospective investigations of the
DIG trial database have found digoxin to have beneﬁcial
effects in high-risk groups regardless of SDC. First, apre-speciﬁed subgroup analysis of the DIG trial found that
patients with NYHA functional class III or IV symptoms,
left ventricular EFs <25%, and cardiothoracic ratios >55%
treated with digoxin had improvements in 2-year outcomes,
including HF-speciﬁc death or hospitalization, all-cause
hospitalization, and all-cause mortality (Fig. 5) (50). Simi-
larly, another study found that digoxin reduces 30-day all-
cause hospitalizations in ambulatory patients with HF 65
years of age, establishing a short-term clinical beneﬁt in
elderly patients (Fig. 6) (51).
Finally, patients randomized to digoxin more commonly
experienced improvements in renal function (deﬁned as
a 20% increase in estimated glomerular ﬁltration rate), a
clinical ﬁnding that was associated with a reduction in
the composite of mortality and hospitalization (52,53).
This ﬁnding is clinically relevant, as cardiorenal interactions
Figure 3
Kaplan-Meier Curves for Cumulative Risk for
All-Cause Mortality and Hospitalization for HF
(A) All-cause mortality; (B) hospitalization for HF. HF ¼ heart failure. Reprinted,
with permission, from Ahmed et al. (45).
Figure 4
Point Estimate and 95% Conﬁdence Intervals of
Hazard of Death From Any Cause for Men and Women
by SDC
SDC ¼ serum digoxin concentration. Reprinted, with permission, from Adams
et al. (49).
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1828are known to contribute to the pathophysiologic progression
of HF, and renal function often limits the initiation and
titration of evidence-based medications (i.e., angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers and mineralocorticoid receptor antagonists) as well
as diuretic therapy. Further research is required to validate
the hypothesis that the long-term beneﬁcial effects of
digoxin are mediated by the preservation or frank recovery of
renal function.
The DIG database was recently reanalyzed to look at the
primary composite end point used in the SHIFT (Systolic
Heart Failure Treatment With the If Inhibitor Ivabradine
Trial) to compare the effect of digoxin with that of this
novel agent (54). Treatment with digoxin and ivabradine
resulted in relative risk reductions in CV death or hospital
admission for worsening HF, respectively, of 15% (95% CI:
9% to 21%) and 18% (95% CI: 10% to 25%). There is a
growing recognition that an elevated HR may portend a
poor prognosis and be a potential target for therapy (55).
Ivabradine selectively inhibits the pacemaker If current,slowing the HR by approximately 10 beats/min and thereby
reducing CV morbidity and mortality (56–58). In contrast,
the long-term beneﬁts of digoxin are mediated by facili-
tating overall improvement in cardiac function and are
likely independent of baseline HR and not entirely
explained by modest decreases in HR as a result of its
vagomimetic effects. Thus, although digoxin and ivabradine
have comparable long-term beneﬁts, driven by a reduction
in CV morbidity, their mechanisms of action are distinctly
different, and they should not be viewed as mutually
exclusive alternatives and may in fact be complementary in
terms of clinical utility.
Collectively, the available evidence suggest that higher
digoxin doses achieving SDCs thought to be therapeutic in the
past (i.e., 1.0 to 2.0 ng/ml) do not result in added symptomatic,
hemodynamic, or neurohormonal beneﬁt and may have dele-
terious consequences on long-term survival, irrespective of sex.
However, one of the major criticisms of the aforementioned
studies is that higher SDCmay simply be a surrogate for other
high-risk measured or unmeasured clinical features not
adjusted for in multivariate modeling. In this respect, pro-
spective randomized clinical trial data would be invaluable.
Digoxin Use in Contemporary Clinical Databases
A number of retrospective studies of consecutive patients
(59) and clinical trial databases (60) and prospective cohort
studies (61) have questioned the efﬁcacy and safety of
digoxin therapy. Most notably, a study based on the
AFFIRM (Atrial Fibrillation Follow-Up Investigation of
Figure 5
Kaplan-Meier Plots for Hospitalization or Death Due to HF by Treatment Groups in High-Risk Patients,
Including NYHA Functional Class III or IV, LVEF <25%, and Cardiothoracic Ratio >55% in the DIG Trial
(A) NYHA functional class III or IV; (B) LVEF <25%; (C) cardiothoracic ratio >55%. Reprinted, with permission, from Gheorghiade et al. (50). CI ¼ conﬁdence interval; DIG ¼
Digitalis Investigation Group; HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association.
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1829Rhythm Management) trial found digoxin therapy to be
associated with an increased risk for mortality in patients
independent of the presence or absence of HF (62). How-
ever, the results of this post-hoc analysis of the AFFIRM
trial were challenged by a subsequent study using
propensity-matched cohorts that found no evidence of
increased mortality or hospitalization in patients taking
digoxin at baseline (63).
It should be noted that these studies were non-
randomized and subject to selection bias, because digoxin isFigure 6 Effects of Digoxin on 30-Day Admissions in Subgroups of O
Reprinted, with permission, from Bourge et al. (51). CI ¼ conﬁdence interval; DIG ¼ Digigenerally prescribed to patients with symptomatic HF
despite optimal medical management. Even with sophisti-
cated statistical techniques, it may be challenging to fully
adjust for disease severity comprehensively and the indica-
tion for treatment by the provider. Furthermore, these post-
hoc analyses were all based on prevalent digoxin use, and
substantial differences in clinical characteristics may develop
in the time frame between initial prescription and study
enrollment. Thus, although existing and future adminis-
trative and clinical trial databases may provide usefullder Patients in the DIG Trial
talis Investigation Group.
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and natural history of HF, conclusions regarding the efﬁ-
cacy and safety of speciﬁc treatments should be interpreted
with caution (64,65).
Future Research on Digoxin
Despite the success achieved in the management of HF
with reduced EF in the ambulatory setting, patients with
worsening chronic HF, deﬁned as deteriorating signs and
symptoms on standard therapy often leading to unscheduled
clinic or emergency department visits or hospitalizations,
experience unacceptable rates of CV morbidity and mor-
tality. Digoxin is known to reduce all-cause and HF-speciﬁc
hospitalizations and at lower SDCs (i.e., 0.5 to 0.9 ng/ml)
and in certain high-risk groups (i.e., patients with NYHA
functional class III or IV symptoms, left ventricular EFs
<25%, and cardiothoracic ratios >55%) may improve sur-
vival. Despite safety concerns regarding supratherapeutic
levels and fatal arrhythmias, the absolute incidence of
digoxin toxicity requiring hospitalization is low both in the
controlled setting of a study (6) and in the context of routine
clinical practice (66,67). Thus, these data support a thera-
peutic trial of digoxin in patients experiencing worsening
chronic HF despite standard therapy.
Additionally, the unique pharmacologic properties of
digoxin provide a strong rationale to reevaluate its efﬁcacy
and safety in stable ambulatory patients with HF. It is the
only inotrope known to increase cardiac output and reduce
pulmonary capillary wedge pressure without increasing HR
or decreasing blood pressure. In contrast, despite favorable
hemodynamic actions, alternative oral inotropes have been
associated with higher morbidity and mortality, particularly
in the subset of patients with the worst symptoms (68,69).
Thus, it is notable that digoxin therapy does not have
long-term deleterious consequences, and its hemodynamic
effects are not attenuated by chronic administration (i.e.,
Naþ/Kþ–adenosine triphosphatase is not up-regulated)
(54–57). In addition, digoxin may have synergistic effects
with b-blockers as an adjunct for reducing HR and
mineralocorticoid receptor antagonists for its putative anti-
ﬁbrotic properties (32). Finally, digoxin therapy does not
decrease blood pressure or worsen renal function, side effects
that have traditionally limited the initiation and titration of
several other evidence-based medications and diuretic agents.
It should be noted that the outpatients enrolled in the
DIG trial differ markedly from an unselected contemporary
HF population in terms of demographics (i.e., age, sex, and
ethnicity) and background therapy. Thus, an appropriately
designed and powered randomized, double-blind, placebo-
controlled trial should be conducted to establish the broader
clinical utility of digoxin in stable ambulatory patients with
HF. All study participants should be taking b-blockers,
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers, and mineralocorticoid receptor antago-
nists or have documented intolerance or contraindications.Prespeciﬁed subgroups should include women and elderly
patients. Further trials might include patients with HF with
preserved EF in whom the absolute beneﬁt of digoxin
appeared to be comparable at 2 years, a prespeciﬁed analysis,
but not signiﬁcant at study end, perhaps because of the
smaller sample size and higher proportion of patients lost to
follow-up (42). Similarly, additional research should be
conducted in the 30% to 40% of patients with HF with
comorbid atrial ﬁbrillation in whom the combination of
carvedilol and digoxin has been shown to improve rate
control, left ventricular EF, and symptomatology compared
with either agent alone (70).
The initial maintenance dose of digoxin in future studies
should be based on an algorithm taking into account age,
sex, ideal body weight, and renal function. However, a
starting dose of 0.125 mg/day would be appropriate for
most patients, with a smaller number of patients requiring a
dose of 0.0625 or 0.250 mg/day. Clinician-investigators
should be trained to distinguish between digoxin effect
(i.e., scooped ST-segments), excess (i.e., second-degree
atrioventricular block), intoxication (i.e., ventricular ar-
rhythmias), and overdose (i.e., ventricular arrhythmias and
hyperkalemia). A key question is whether serial SDCs are
required for dose titration and to monitor for safety. In
the DIG trial, although there were more patients in the
digoxin arm with suspected clinical toxicity (11.9% vs.
7.9%), the proportion of patients requiring hospitalization
for digoxin toxicity was low (2.0% vs. 0.9%) over a period of
3.5 years. Furthermore, outside of the context of a clinical
trial, the incidence of digoxin toxicity has been estimated
to be as low as 1% to 5% (66,67), and >95% of cases occur
in patients with SDCs >2.0 ng/ml (71). Thus, with
appropriate digoxin dosing, it may not be necessary to
routinely measure SDCs in most patients to achieve a safe
and efﬁcacious level.
Although the gold standard for efﬁcacy and safety will
continue to be all-cause mortality, there is growing recog-
nition that the “patient journey” may include impairments
in day-to-day experience that are not fully captured by
traditional outcome measures. Thus, validated patient-
centered supplementary end points may be necessary to
ascertain the net clinical beneﬁt of existing and novel in-
terventions. Given the renewed interest in reducing 30-day
readmissions, hospitalization-free survival is a logical choice
for long-term efﬁcacy. Candidate endpoints for short-term
clinical status might include the percentage of patients with
worsening dyspnea, physician-assessed signs and symptoms,
functional capacity, and quality of life. Finally, measuring
echocardiographic parameters (ﬁlling pressures, chamber
size, EF, and so on) and neurohormonal (norepinephrine,
plasma renin activity, aldosterone, and so on) and biomarker
levels (i.e., natriuretic peptide concentration) in at least a
subset of patients might clarify the relative contribution of
the hemodynamic and neurohormonal properties of digoxin
on short-term and long-term morbidity and mortality in the
current era of lower target SDCs and background therapy
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hibitors or angiotensin receptor blockers, and mineralo-
corticoid receptor antagonists.
Conclusions
Patients with worsening chronic HF, deﬁned as deterio-
rating signs and symptoms on standard therapy often lead-
ing to unscheduled clinic or emergency department visits or
hospital admissions, experience clinical, hemodynamic, and
neurohormonal deterioration despite recommended drug
and device-based therapy. Digoxin is known to ameliorate
signs and symptoms of HF, improve functional status, and
reduce all-cause and HF-speciﬁc hospitalizations. Thus, a
therapeutic trial of digoxin should be considered in patients
with HF with reduced EF who remain symptomatic and at
high-risk for admission despite medical management.
Future research should be conducted to assess the efﬁcacy
and safety of digoxin in a more contemporary cohort of
stable patients with HF, including those with preserved EFs
and/or concomitant atrial ﬁbrillation.
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